- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Fr | REVIVA PHARMACEUTICALS HOLDINGS, INC. - 8-K, Current Report | 2 | SEC Filings | ||
| Mo | Reviva reports positive year-long schizophrenia drug study | 1 | Investing.com | ||
| REVIVA PHARMACEUTICALS Aktie jetzt für 0€ handeln | |||||
| Mo | Reviva Pharmaceuticals: Reviva Announces Positive Full Dataset for 1-Year Phase 3 RECOVER Open Label Extension Study Evaluating Brilaroxazine in Schizophrenia | 217 | GlobeNewswire (Europe) | - Robust broad-spectrum efficacy sustained over 1-year across all symptom domains including negative symptoms - - Generally well-tolerated with low rates of adverse events and discontinuation... ► Artikel lesen | |
| 30.05. | REVIVA PHARMACEUTICALS HOLDINGS, INC. - 8-K, Current Report | 2 | SEC Filings | ||
| 24.05. | Benchmark hält 14 US-Dollar Kursziel für Reviva Pharmaceuticals-Aktie aufrecht | 2 | Investing.com Deutsch | ||
| 20.05. | Reviva stock target cut to $3 on cash concerns, retains Buy rating | 4 | Investing.com | ||
| 15.05. | Reviva Pharmaceuticals GAAP EPS of -$0.13 | 1 | Seeking Alpha | ||
| 15.05. | Reviva Pharmaceuticals: Reviva Reports First Quarter 2025 Financial Results and Recent Business Highlights | 69 | GlobeNewswire (Europe) | - 446 participants completed the brilaroxazine long-term open-label extension (OLE) trial with 156 completing one-year and 301 completing six months of treatment - - Full data set from RECOVER OLE... ► Artikel lesen | |
| 09.04. | Reviva Pharmaceuticals target cut to $14 by Benchmark | 2 | Investing.com | ||
| 03.04. | REVIVA PHARMACEUTICALS HOLDINGS, INC. - S-8, Securities to be offered to employees in employee benefit plans | - | SEC Filings | ||
| 31.03. | REVIVA PHARMACEUTICALS HOLDINGS, INC. - NT 10-K, Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 | 3 | SEC Filings | ||
| 31.03. | Reviva Pharmaceuticals GAAP EPS of -$0.90 beats by $0.07 | 2 | Seeking Alpha | ||
| 31.03. | Reviva Pharmaceuticals: Reviva Reports Full Year 2024 Financial Results and Recent Business Highlights | 113 | GlobeNewswire (Europe) | - Favorable long-term safety and robust broad-spectrum efficacy sustained over 1-year for once daily brilaroxazine in open-label extension (OLE) trial - - Registrational Phase 3 RECOVER-2 trial initiation... ► Artikel lesen | |
| 31.03. | REVIVA PHARMACEUTICALS HOLDINGS, INC. - 8-K, Current Report | 2 | SEC Filings | ||
| 30.03. | Reviva Pharmaceuticals: Reviva to Present Brilaroxazine Topline Data for Long-Term OLE Portion of RECOVER Study in Schizophrenia at 2025 SIRS Congress | 2 | GlobeNewswire (USA) | ||
| 18.02. | REVIVA PHARMACEUTICALS HOLDINGS, INC. - 8-K, Current Report | 1 | SEC Filings | ||
| 07.01. | Reviva Pharmaceuticals: Reviva to Participate in the Lytham Partners 2025 Investor Healthcare Summit | 2 | GlobeNewswire (USA) | ||
| 17.12.24 | Reviva announces pricing of $18M public offering of common stock and warrants | 16 | Seeking Alpha | ||
| 16.12.24 | Reviva Pharmaceuticals: Reviva Announces Proposed Public Offering | 3 | GlobeNewswire (USA) | ||
| 16.12.24 | Reviva's antipsychotic shows promise against schizophrenia symptoms in year-long study | 3 | FierceBiotech |
1 2 Weiter >>
25 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BAYER | 26,435 | +0,02 % | Bayer, Vidac Pharma, Evotec - schnappen Sie sich den 866 Milliarden Onkologie Jackpot | Die Onkologie erlebt eine beispiellose Revolution. Mit prognostizierten 866 Mrd. USD Marktvolumen bis 2034 und 11 % Jahreswachstum treiben KI-gestützte Diagnosen, personalisierte Gentherapien und Präzisionsmedizin... ► Artikel lesen | |
| PFIZER | 20,510 | +0,15 % | Goldgrube US-Gesundheitswandel: Wie sind Bayer, PanGenomic Health und Pfizer aufgestellt? | Das US-Gesundheitswesen erlebt unter Minister Robert F. Kennedy Jr. einen beispiellosen Umbruch. Pharmariesen ächzen unter drastischen Preiskontrollen und regulatorischen Erdbeben, während digitale... ► Artikel lesen | |
| ROCHE | 285,50 | -0,21 % | IBM und Roche entwickelten gemeinsam eine innovative Lösung, die Menschen mit Diabetes mit KI-gestützten Glukosevorhersagen in ihrem Alltag unterstützt | Zürich - IBM und Roche haben ihre gemeinsame Innovationskraft genutzt und eine KI-basierte Lösung entwickelt, um das tägliche Diabetes-Management zu vereinfachen: die Accu-Chek® SmartGuide Predict App... ► Artikel lesen | |
| VIATRIS | 7,584 | -0,73 % | Viatris Reports Positive Top-line Results From LYNX-2 Phase 3 Trial With MR-142 | WASHINGTON (dpa-AFX) - Viatris (VTRS) reported positive top-line results from LYNX-2, a Phase 3 trial evaluating MR-142 in treating significant, chronic night driving impairment in keratorefractive... ► Artikel lesen | |
| GREEN THUMB INDUSTRIES | 4,600 | +0,97 % | Green Thumb Industries Inc: Green Thumb to hold cannabis, music festival | ||
| CASSAVA SCIENCES | 1,892 | -0,29 % | Cassava Sciences, Inc.: Cassava Announces Retirement of Chief Medical Officer, Dr. Jim Kupiec, and Appointment of Dr. Jack Moore as Senior Vice President, Clinical Development | AUSTIN, Texas, April 21, 2025 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ: SAVA, "Cassava", the "Company"), a clinical-stage biotechnology company focused on developing novel, investigational... ► Artikel lesen | |
| NEWRON PHARMACEUTICALS | 8,360 | -0,48 % | Newron Pharmaceuticals - Next stage unlocked for evenamide | Newron has announced receipt of regulatory clearance to conduct its Phase III programme for evenamide (ENIGMA-TRS), taking it one step closer to the market. It will comprise two separate trials: ENIGMA-TRS... ► Artikel lesen | |
| ORAMED PHARMACEUTICALS | 1,910 | -2,20 % | Oramed Pharmaceuticals Inc.: Oramed Pharmaceuticals Announces $36.9 Million Investment and Strategic Collaboration with Alpha Tau Medical | Oramed leverages its strategic capital markets expertise to support Alpha Tau's breakthrough cancer therapy technology
Accelerating multiple late-stage cancer therapies... ► Artikel lesen | |
| ACHIEVE LIFE SCIENCES | 3,150 | -6,11 % | Achieve Life Sciences hält Jahreshauptversammlung mit wichtigen Abstimmungen ab | ||
| AURINIA PHARMACEUTICALS | 7,120 | -0,86 % | Aurinia Pharmaceuticals Inc. - S-8, Securities to be offered to employees in employee benefit plans | ||
| KAZIA THERAPEUTICS | 5,550 | +2,40 % | Kazia Therapeutics Limited: Kazia Therapeutics Announces First Patient Dosed in Phase 1b Trial of Paxalisib in Advanced Breast Cancer | Trial is expected to provide key insights on how paxalisib therapy can be combined with established immunotherapies and standard of care chemotherapy to improve... ► Artikel lesen | |
| LIPOCINE | 3,110 | -2,05 % | Lipocine Inc. - 8-K, Current Report | ||
| ALLERGY THERAPEUTICS | 0,072 | -8,86 % | Allergy Therapeutics half-year loss narrows on lower expenses | ||
| SUNSHINE BIOPHARMA | 1,510 | +2,03 % | Sunshine Biopharma Inc.: Sunshine Biopharma Reports 2025 First Quarter Results, Revenues Up 18% Over Same Period Last Year | FORT LAUDERDALE, FL / ACCESS Newswire / May 15, 2025 / Sunshine Biopharma Inc. (NASDAQ:SBFM) (the "Company"), a pharmaceutical company offering and researching life-saving medicines in a variety of... ► Artikel lesen | |
| MERCK KGAA | 115,20 | -0,17 % | Aktie von Merck legt um 0,83 Prozent zu (116,00 €) | Das Wertpapier von Merck notiert heute fester. Die Aktie kostete zuletzt 116,00 Euro. Heute hat sich am deutschen Aktienmarkt die Merck-Aktie zwischenzeitlich um 0,83 Prozent verteuert. Der Kurs des... ► Artikel lesen |
REVIVA PHARMACEUTICALS HOLDINGS INC gehört der Branche Pharma an. Der aktuelle Kurs liegt bei 0,826 Euro und damit +3,21 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu REVIVA PHARMACEUTICALS HOLDINGS INC finden Sie auf Wallstreet Online.